Abstract:Abstract Disclosure: S.S. Awasty: None. L. Ghalib: None. Background: A Thyrotropinoma or TSHoma is the rarest of all pituitary adenomas approximately 1-2%. TSHomas are often only found due to symptoms from co-secreting tumors with TSHomas or routine laboratory testing. Misinterpretation of laboratory values can cause misdiagnosis and inappropriate treatment. Clinical Case: A 45-year-old female presented to her primary care physician for a routine appointment. The patient reported concerns regarding weight and a TSH was ordered, TSH 7.00 uIU/mL (0.49 - 4.67) with no other thyroid function values. The physician prescribed levothyroxine 50mcg treating for primary hypothyroidism and over the next 37 months the patient was prescribed increasing doses of levothyroxine based on TSH values. This patient was eventually referred to Endocrinology. At the initial Endocrinology visit TSH 7.59 uIU/mL (0.27 - 4.2 uIU/mL) and fT4 3.2 ng/dL (0.7 - 1.7) on levothyroxine 125mcg. Levothyroxine was discontinued and labs were repeated 6 weeks later TSH 5.9 uIU/mL (0.27 - 4.2), fT4 4.8 ng/dL (0.7 - 1.7), fT3 2.1 pg/mL (2 - 4.4), and alpha-subunit 1.5ng/mL (<=1.2 premenopausal female, <=1.8 postmenopausal female). A pituitary macroadenoma was discovered on MRI. The patient was referred to Pituitary Clinic and noted to have a prolactin of 53.8 ng/mL (non-pregnant females 2.8-29.2) and IGF-1 291.6 ng/mL (60.0 - 240.0). The patient underwent transsphenoidal pituitary surgery; pathology reported a plurihormonal subtype pituitary adenoma which stained positive for Prolactin, HGH, and TSH. One week after removal of the TSHoma, TSH 0.014 uIU/mL (0.550 - 4.780) fT4 0.65 ng/dL (0.89 - 1.76), and levothyroxine replacement was initiated with plans for continued outpatient monitoring to assess need for levothyroxine replacement. Conclusion: This case primarily demonstrates the importance of evaluating TSH levels in conjunction with free T4 levels to effectively interpret central versus primary causes of thyroid dysfunction. The high molar ratio of the alpha-subunit to the TSH level lends itself to a TSHoma differentiating it from a diagnosis of syndrome of resistance to thyroid hormone. While rare missing a TSHoma diagnosis could have devastating consequences. Checking other pituitary hormones pre-operatively even without symptoms also gave the indication that this was a co-secreting tumor. After adenoma removal rechecking pituitary hormones is of great importance as exemplified by pituitary-thyroid axis suppression noted post-operatively in this case. Presentation: Thursday, June 15, 2023

Diagnosing Thyrotropin-Secreting Pituitary Adenomas by Short-Term Somatostatin Analogue Test

Syndrome of Inappropriate Secretion of TSH : Differential Diagnosis in 61 Patients

Predictive Value of T2 Relative Signal Intensity for Response to Somatostatin Analogs in Newly Diagnosed Acromegaly

The Value of an Acute Octreotide Suppression Test in Predicting Short-Term Efficacy of Somatostatin Analogues in Acromegaly

Efficacy and Predictors of Short-Term First-Generation Somatostatin Analog Presurgical Treatment in Acromegaly: A Hospital-Based Study of 237 Cases.

Early identification of postoperative remission for thyrotropin‐secreting adenomas

THU096 When TSH Alone Is Not Enough

TSH adenoma and syndrome of resistance to thyroid hormones—Two cases report of syndrome of inappropriate secretion of thyrotropin

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Presurgical Treatment with Somatostatin Analogues in Growth Hormone-Secreting Pituitary Adenomas: A Long-Term Single-Center Experience

[Thyroid-stimulating hormone pituitary adenomas: clinical characteristics, diagnosis and treatment]

Clinical characteristics and diagnostic analysis of thyrotropinoma

Preoperative long-acting somatostatin analogs in treatment of growth-hormone secreting pituitary adenoma

A challenging case of a pituitary macroadenoma and toxic thyroid adenoma with inappropriate TSH secretion

[A Clinical Analysis of Thyrotropin-Secreting Pituitary Adenomas in 20 Patients].

Thyrotropin-Secreting Pituitary Adenomas:a Case Report and Literature Review

Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients with Differentiated Thyroid Carcinoma.

[Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients]

Stimulating Thyroglobulin to TSH Ratio Predict Long-Term Efficacy of 131 I Therapy in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy: a Retrospective Study

Utility of recombinant human TSH stimulation test in the follow-up of patients with differentiated thyroid cancer depending on basal thyroglobulin results